Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA topoisomerase 2-alpha (TOP2A) is an essential eukaryotic type IIA topoisomerase that functions as a homodimer to alter DNA topology by creating transient, ATP‑dependent double‑strand breaks and passing a second DNA segment through the break; it is crucial for decatenation of sister chromatids, chromosome condensation, and faithful chromosome segregation in proliferating cells. Human Top2α is the primary isoform targeted by frontline anticancer agents that form ternary drug–enzyme–DNA cleavage complexes; structural and cryo‑EM studies reveal the “two‑gate” mechanism, active‑site residues (including catalytic Tyr805 in human Top2α), and allosteric coupling between the ATPase and DNA‑cleavage cores that underlie drug action and opportunities for isoform‑selective inhibition.
Topoisomerase II poison: drugs such as doxorubicin and etoposide stabilize the Top2α–DNA cleavage complex, producing persistent double‑strand breaks that trigger cell death in dividing cells
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA topoisomerase 2-alpha (TOP2A).